Date: 2015-02-09
Type of information: Licensing agreement
Compound: PP-001 - 3-{[2,3,5,6-tetrafluoro-3\'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid
Company: Panoptes Pharma (Austria) Mediolanum Farmaceutici (Italy)
Therapeutic area: Ophtalmological diseases - Inflammatory diseases - Rare diseases
Type agreement: licensing
Action mechanism: enzyme inhibitor. PP-001 is a specific nanomolar inhibitor of an essential enzyme of the de novo pyrimidine pathway leading to inhibition of expression of IFN-γ and IL-17, two hallmark cytokines of Th1 and Th17 cells responsible for autoimmune uveitis and other inflammatory diseases. Further, PP-001 reduces the host cell pyrimidine pool, which leads to inhibition of replication of many viruses especially adenovirus serotypes causing the highly contagious viral form of conjunctivitis.
Disease: inflammatory eye diseases including non-infectious uveitis
Details: * On February 9, 2015, Panoptes Pharma announced that it has entered into an agreement with Mediolanum Laboratoires Leurquin S.A., the wholly owned French subsidiary of the Italian company Mediolanum Farmaceutici S.p.A.. Under the terms of the agreement, Mediolanum will acquire marketing rights to PP-001, a small molecule which is currently in preclinical development as potential next generation treatment for several inflammatory eye diseases including non-infectious uveitis. PP-001 is a selective anti-inflammatory small molecule compound which has demonstrated efficacy in preclinical models in ophthalmology. Additionally, PP-001 significantly inhibits abnormal blood vessel growth in the back of the eye (choroidal neovascularization) in an animal model for autoimmune uveitis. Inhibition of choroidal neovascularization (CNV) is mediated by the inhibition of vascular endothelial growth factor (VEGF) by PP-001.
Financial terms: Under the terms of the agreement, Panoptes received an upfront payment, and is eligible for developmental and sales milestones and royalties on net sales. Mediolanum will have marketing rights over two main European countries, while Panoptes will retain marketing rights in all other countries. Other terms of the deal were not disclosed.
Latest news:
